Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296112 · ClinicalTrials.gov registry record · Phase 2
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02296112 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT02296112, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG trametinib
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-01 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296112
The ClinicalTrials.gov registry entry for NCT02296112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02296112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296112 about?
NCT02296112 is a clinical study titled "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations". This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02296112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-01. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT02296112?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trametinib (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT02296112?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.